RECEIVED
CENTRAL FAX CENTER
OCT 11 2006

IN THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

Claims 1-34 (Canceled)

Claim 35 (Currently amended): A composition for generating an immune response to a human prostate tumor-associated antigen in a human subject, comprising:

a proliferation-incompetent cell engineered to express GM-CSF selected from ~~the group consisting of~~ LnCaP[[,]]and PC3 ~~and DU145~~, wherein said composition is capable of eliciting elicits a humoral immune response to a prostate tumor-associated antigen with a molecular weight selected from the group consisting of 250 kD, 160 kD, 150 kD, 31 kD, 26 kD and 14 kD, as detected by SDS-PAGE, wherein said humoral immune response is not detected in said human subject prior to administering said composition and said prostate tumor-associated antigen does not cross-react immunologically with prostate-specific antigen.

Claim 36 (Previously Presented): The composition of Claim 35, wherein said proliferation-incompetent cell is an LnCaP cell.

Claim 37 (Previously Presented): The composition of Claim 35, wherein said proliferation-incompetent cell is a PC3 cell.

Claim 38 (Cancelled)

Claim 39 (Previously Presented): The composition of Claim 36, further comprising a proliferation-incompetent PC3 cell.

Claim 40 (Previously Presented): The composition of Claim 35, wherein said prostate tumor-associated antigen has a molecular weight of 250 kD.

Claims 41- 43 (Canceled)

Claim 44 (Previously Presented): The composition of Claim 39, wherein said LnCaP and PC3 cells are administered to said human subject in equal doses.

Claim 45 (Previously Presented): The composition of Claim 44, wherein said dose of LnCaP and PC3 cells is 6 x 107 cells per cell type.

Claim 46 (Previously Presented): The composition of Claim 39, wherein said LnCaP and PC3 cells are administered subcutaneously.

Claim 47 (Previously Presented): The composition of Claim 39, wherein said LnCaP and PC3 cells express 200-300 ng GM-CSF per 106 cells.

Claim 48 (Withdrawn): A method for generating an immune response to a prostate tumor-associated antigen, comprising:

administering to a human subject a GM-CSF-expressing proliferation-incompetent cell selected from the group consisting of LnCaP, PC3 and DU145, wherein a humoral immune response to a prostate tumor-associated antigen with a molecular weight selected from the group consisting of 250 kD, 160 kD, 150 kD, 31 kD, 26 kD and 14 kD, is detected by SDS-PAGE subsequent to said administering, wherein said humoral immune response is not detected in said human subject by said SDS-PAGE prior to said administering and said prostate tumor-associated antigen does not cross-react immunologically with prostate-specific antigen.

Claim 49 (Withdrawn): The method of Claim 48, wherein said proliferation-incompetent cell is an LnCaP cell.

Claim 50 (Withdrawn): The method of Claim 48, wherein said proliferation-incompetent cell is a PC3 cell.

Claim 51 (Withdrawn): The method of Claim 48, wherein said proliferation-incompetent cell is a DU145 cell.

Claim 52 (Withdrawn): The method of Claim 49, further comprising a proliferation-incompetent PC3 cell.

Claim 53 (Withdrawn): The method of Claim 48, wherein said prostate tumor-associated antigen has a molecular weight of 250 kD.

Claim 54 (Withdrawn): The method of Claim 52, wherein said LnCaP and PC3 cells are administered to said human subject in equal doses.

Claim 55 (Withdrawn): The method of Claim 54, wherein said dose of LnCaP and PC3 cells is 6 x 107 cells per cell type.

Claim 56 (Withdrawn): The method of Claim 52, wherein said LnCaP and PC3 cells are administered subcutaneously.

Claim 57 (Withdrawn): The method of Claim 52, wherein said LnCaP and PC3 cells express 200-300 ng GM-CSF per 106 cells.

Claim 58 (Withdrawn): The composition of Claim 39, wherein said LnCaP and PC3 cells are administered intradermally.

Claim 59 (Withdrawn): The method of Claim 52, wherein said LnCaP and PC3 cells are administered intradermally.